Consequently, the study concluded that employing a sensitive assay to measure cTnI can forecast disease severity and prognosis in PAH patients and identify individuals at increased risk of death related to right ventricular failure or transplant. This evidence concerns the gene TNNI3 and pulmonary arterial hypertension.